OncRef

Clinical Trial: NCT01905046

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Alliance for Clinical Trials in Oncology
Information Provided By:Alliance for Clinical Trials in Oncology
Last Update Posted:2026-10-08

Study Overview

Brief Summary

This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.

Official Title

Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women

Conditions

Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ

Intervention / Treatment

  • Drug: metformin hydrochloride
  • Other: placebo

Other Study ID Numbers

  • A211102
  • U10CA031946
  • NCI-2013-00995

Start Date (Actual)

2015-11-23

Primary Completion Date (Actual)

2023-11-10

Study Completion Date (Estimated)

2026-11

Enrollment (Actual)

86

Study Type

Interventional

Phase

Phase 3